BIOMAT Database Logo BIOMAT Database Logo

[Evaluation of combination chemotherapy for advanced gastric carcinoma as a neoadjuvant chemotherapy with CDDP, MMC, etoposide and 5'-DFUR]. 1994

T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
Second Dept. of Internal Medicine, Showa University School of Medicine.

Seven cases of nonresectable gastric carcinoma with lymph node metastasis were treated with combination chemotherapy [CDDP 75 mg/m2 i.v. day 1 (A method: Ccr > or = 50 ml/min) or 20 mg/m2 i.v. day 1, 2, 4, 5 (B method: Ccr < 50 ml/min), MMC 10 mg/m2 i.v. day 1, etoposide 50 mg/body i.v. day 3, 4, 5, 5'-DFUR 2,100 mg/body po 4 day/week] every 4 weeks as a neoadjuvant chemotherapy. After treatment, the size of the primary tumor was reduced in four of seven cases. The lymph nodes disappeared in one case and were reduced in size in four cases. Metastatic liver tumors were found in four cases. They disappeared in one case and the size was reduced in one of seven cases. One patient with renal dysfunction was treated with B method. However, renal dysfunction did not become worse. Five patients were operated after chemotherapy. Absolute curative resection was performed in three of them. The total rate of curative resection was 43% (3/7). Four patients were alive for 19 months after operation. The main side effects of this therapy were nausea, anorexia and bone marrow suppression, which, were found in all patients. These results suggest that this combination chemotherapy is as effective as neoadjuvant chemotherapy for advanced gastric carcinoma.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D005467 Floxuridine An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. FUdR,Fluorodeoxyuridine,5-FUdR,5-Fluorodeoxyuridine,5 Fluorodeoxyuridine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[A case of cutaneous and brain metastasis of gastric carcinoma, treated effectively by chemotherapy with CDDP, MMC, etoposide and 5'-DFUR].
November 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[A case of nonresectable advanced gastric cancer responding to combined chemotherapy with 5'-DFUR, CDDP, and MMC].
June 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[Successful 5'-DFUR, CDDP and MMC combination therapy and 5'-DFUR and carboplatin combination therapy for a patient with inoperable advanced gastric cancer with peritonitis carcinomatosa].
May 1997, Gan to kagaku ryoho. Cancer & chemotherapy,
T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[Effect of CDDP/5'-DFUR combination chemotherapy for advanced or recurrent gastric cancer].
October 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[Combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16) and 5'-DFUR, (MACVD therapy) as a second-line chemotherapy for metastatic gastric cancer: three cases].
June 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[Combination therapy with 5'-DFUR, MMC and CDDP in patient with far advanced gastric cancer: report of a case].
August 1997, Gan to kagaku ryoho. Cancer & chemotherapy,
T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[Neoadjuvant chemotherapy of far advanced gastric cancer--effect of preoperative chemotherapy by PMUE (CDDP, MMC, UFT, etoposide].
March 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[Combination chemotherapy with etoposide, ADM, and CDDP (EAP) for advanced gastric cancer].
November 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[Process of making a protocol for advanced gastric cancer chemotherapy--using 5'-DFUR+CDDP as an example].
December 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
T Itoh, and K Anzai, and M Ishii, and H Nishida, and T Kawada, and Y Akita, and M Onuki, and K Mitamura, and M Kawamura, and K Arai
[Combination chemotherapy of UFT, etoposide and CDDP in advanced gastric cancer].
June 1987, Gan no rinsho. Japan journal of cancer clinics,
Copied contents to your clipboard!